Artículos por temáticas

Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease

Sharma A, Bemis M, Desilets AR.

Am J Alzheimers Dis Other Demen. 2014 Aug;29(5):409-14. doi: 10.1177/1533317513518650. Epub 2014 Jan 9.

The elusive search for solutions to Alzheimer's

Iglehart JK.

Health Aff (Millwood). 2014 Apr;33(4):526. doi: 10.1377/hlthaff.2014.0253.

The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer's Disease

Nagase H, Nakayama K.

Curr Drug Discov Technol. 2014;11(4):243-58. doi: 10.2174/1570163811666141121101358.

Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia

Frampton JE.

Drugs Aging. 2014 Aug;31(8):639-49. doi: 10.1007/s40266-014-0197-x.

The National Alzheimer's Project Act... Missed opportunities from a caregiver's perspective

Vann AS.

J Am Geriatr Soc. 2014 May;62(5):966-7. doi: 10.1111/jgs.12778.

Galantamine treatment in outpatients with mild Alzheimer's disease

Richarz U, Gaudig M, Rettig K, Schauble B.

Acta Neurol Scand. 2014 Jun;129(6):382-92. doi: 10.1111/ane.12195. Epub 2014 Jan 25.

Cognitive-behavioural group therapy improves a psychophysiological marker of stress in caregivers of patients with Alzheimer's disease

Aboulafia-Brakha T, Suchecki D, Gouveia-Paulino F, Nitrini R, Ptak R.

Aging Ment Health. 2014;18(6):801-8. doi: 10.1080/13607863.2014.880406. Epub 2014 Feb 5.

Motor effects of radio electric asymmetric conveyer in Alzheimer's disease: results from a cross-over trial

Olazarán J, González B, Osa-Ruiz E, Felipe-Ruiz S, Boyano I, Fontani V, Castagna A, Mendoza C, Zea MA, Frades B, Rinaldi S, Martínez-Martín P.

J Alzheimers Dis. 2014;42(1):325-32. doi: 10.3233/JAD-140417.

Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers?

Caraci F, Castellano S, Salomone S, Drago F, Bosco P, Di Nuovo S.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):173-86. doi: 10.2174/18715273113129990103.

Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study

Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S.

Int Clin Psychopharmacol. 2014 Jul;29(4):216-23. doi: 10.1097/YIC.0000000000000032.

Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services

Wattmo C, Londos E, Minthon L.

Clin Interv Aging. 2014 Nov 14;9:1951-62. doi: 10.2147/CIA.S71709. eCollection 2014.

Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease

Rodrigues Simões MC, Dias Viegas FP, Moreira MS, de Freitas Silva M, Riquiel MM, da Rosa PM, Castelli MR, dos Santos MH, Soares MG, Viegas C Jr.

Mini Rev Med Chem. 2014 Jan;14(1):2-19. doi: 10.2174/1389557513666131119201353.

Treadmill training as an augmentation treatment for Alzheimer's disease: a pilot randomized controlled study

Arcoverde C, Deslandes A, Moraes H, Almeida C, Araujo NB, Vasques PE, Silveira H, Laks J.

Arq Neuropsiquiatr. 2014 Mar;72(3):190-6. doi: 10.1590/0004-282X20130231.

Impact of Alzheimer's Disease on Caregiver Questionnaire: internal consistency, convergent validity, and test-retest reliability of a new measure for assessing caregiver burden

Cole JC, Ito D, Chen YJ, Cheng R, Bolognese J, Li-McLeod J.

Health Qual Life Outcomes. 2014 Sep 4;12:114. doi: 10.1186/s12955-014-0114-3.

Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial

Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J

PLoS One. 2014 Jun 10;9(6):e98426. doi: 10.1371/journal.pone.0098426. eCollection 2014.